UC Irvine Medical Center

The trials here

What the 30 trials at this site are about, from their registry records.

Conditions

• Stroke5 trials
• Melanoma4 trials
• Colorectal cancer3 trials
• Epilepsy3 trials
• Duchenne muscular dystrophy2 trials
• Kidney cancer2 trials
• Liver and biliary tract cancer2 trials
• Lung cancer2 trials
• Prostate cancer2 trials
• Acute lymphoblastic leukaemia1 trial
• Acute myeloid leukaemia1 trial
• Atrial fibrillation1 trial
• and 12 more

Phase

• Phase 313 trials
• Phase 29 trials
• Phase 1/25 trials
• Phase 12 trials

Status

• Completed10 trials
• Recruiting9 trials
• Active, not recruiting5 trials
• Enrolling by invitation3 trials
• Terminated3 trials

Lead sponsor

• Hoffmann-La Roche5 trials
• Edgewise Therapeutics, Inc.2 trials
• Joseph Broderick, MD2 trials
• Neurona Therapeutics2 trials
• Novartis Pharmaceuticals2 trials
• and 15 more

Running trials

• Enrolling by invitation

  Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

  NCT06773936· Phase 2· SWOG Cancer Research Network· Source

• Enrolling by invitation

  Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

  NCT07062354· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  NCT06902558· Phase 2· Calico Life Sciences LLC· Source

  Contact: Ahmad Walid Roshan

• Recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

  NCT07227246· Phase 3· Joseph Broderick, MD· Source

  Contact: Jay Shah, MD

• Recruiting

  Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases

  NCT06626919· Phase 1· Kite, A Gilead Company· Source

• Recruiting

  An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

  NCT05066217· Phase 3· Epygenix· Source

  Contact: Juby Philip

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

  NCT06609005· Phase 1/2· Shenzhen Ionova Life Sciences Co., Ltd.· Source

  Contact: Hazel Dimasuay

• Recruiting

  A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

  NCT06422923· Phase 1/2· Neurona Therapeutics· Source

  Contact: UCI Alpha Clinic

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  NCT06649110· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Bassam Yaghmour (principal investigator)

• Active, not recruiting

  A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

  NCT06157892· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Enrolling by invitation

  Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

  NCT06066580· Phase 2· Edgewise Therapeutics, Inc.· Source

• Active, not recruiting

  Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

  NCT05047172· Phase 3· University of Florida· Source

• Recruiting

  Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

  NCT05135091· Phase 3· Neurona Therapeutics· Source

  Contact: UCI Alpha Clinic

• Active, not recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

  NCT03496883· Phase 3· Joseph Broderick, MD· Source

• Recruiting

  Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System

  NCT04798261· Penumbra Inc.· Source

  Contact: Joanne Krasnoff

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

  NCT04524871· Phase 1/2· Hoffmann-La Roche· Source

• Recruiting

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

  NCT03907046· Phase 3· Yale University· Source

  Contact: Wengui Yu, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy2 recruiting
• Stroke2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Myasthenia gravis1 recruiting
• Polycystic kidney disease1 recruiting
• Prostate cancer1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Terminated

  Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

  NCT05909995· Phase 1· Incyte Corporation· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· Phase 2· Hoffmann-La Roche· Source

• Completed

  Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

  NCT05291091· Phase 2· Edgewise Therapeutics, Inc.· Source

• Terminated

  A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

  NCT05348915· Phase 3· Pfizer· Source

• Completed

  A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

  NCT04266795· Phase 2· Takeda· Source

• Completed

  Multi-arm Optimization of Stroke Thrombolysis

  NCT03735979· Phase 3· Washington University School of Medicine· Source

• Completed

  M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT03631706· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

  NCT03259035· Phase 2· Canadian Cancer Trials Group· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Hoffmann-La Roche· Source

• Completed

  Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

  NCT03037385· Phase 1/2· Hoffmann-La Roche· Source

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Pfizer· Source